Alliance Global Partners raised the firm’s price target on Abeona Therapeutics (ABEO) to $25 from $20 and keeps a Buy rating on the shares after the company reported Q4 results and highlighted ongoing pre-approval efforts for lead prademagene zamikeracel gene therapy for recessive dystrophic epidermolysis bullosa. The firm values pz-cel for RDEB at $21 per share, the potential Priority Review Voucher for pz-cel at $3 per share, and the remaining pipeline at $1 per share, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue